JP2018514511A5 - - Google Patents

Download PDF

Info

Publication number
JP2018514511A5
JP2018514511A5 JP2017550122A JP2017550122A JP2018514511A5 JP 2018514511 A5 JP2018514511 A5 JP 2018514511A5 JP 2017550122 A JP2017550122 A JP 2017550122A JP 2017550122 A JP2017550122 A JP 2017550122A JP 2018514511 A5 JP2018514511 A5 JP 2018514511A5
Authority
JP
Japan
Prior art keywords
composition
oil
composition according
carcinoma
breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017550122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514511A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/026170 external-priority patent/WO2016168021A1/en
Publication of JP2018514511A publication Critical patent/JP2018514511A/ja
Publication of JP2018514511A5 publication Critical patent/JP2018514511A5/ja
Pending legal-status Critical Current

Links

JP2017550122A 2015-04-14 2016-04-06 乳房障害とエストロゲン関連障害の処置のための組成物と方法 Pending JP2018514511A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562147536P 2015-04-14 2015-04-14
US62/147,536 2015-04-14
PCT/US2016/026170 WO2016168021A1 (en) 2015-04-14 2016-04-06 Compositions and methods of treatment of breast disorders and estrogen-related disorders

Publications (2)

Publication Number Publication Date
JP2018514511A JP2018514511A (ja) 2018-06-07
JP2018514511A5 true JP2018514511A5 (cg-RX-API-DMAC7.html) 2019-04-11

Family

ID=57127000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017550122A Pending JP2018514511A (ja) 2015-04-14 2016-04-06 乳房障害とエストロゲン関連障害の処置のための組成物と方法

Country Status (7)

Country Link
US (1) US20180049999A1 (cg-RX-API-DMAC7.html)
EP (1) EP3283061A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018514511A (cg-RX-API-DMAC7.html)
CN (1) CN107708678A (cg-RX-API-DMAC7.html)
AU (1) AU2016247674A1 (cg-RX-API-DMAC7.html)
CA (1) CA2981301A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016168021A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180169034A1 (en) * 2015-06-14 2018-06-21 Trs Ii, Llc Transdermal delivery formulation
CA2992282A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
CN110099680B (zh) 2016-10-11 2021-02-05 杜克大学 Er+乳腺癌的拉索昔芬治疗
CN111212635A (zh) * 2017-09-11 2020-05-29 阿托莎医疗公司 局部用组合物
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
TW201919594A (zh) * 2017-09-11 2019-06-01 美商艾陶莎基因有限公司 局部用組合物及治療方法
CA3094072A1 (en) * 2018-03-15 2019-09-19 Atossa Therapeutics, Inc. In situ methods of inducing of immune response
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
WO2019232485A1 (en) * 2018-05-31 2019-12-05 Nvigen, Inc. Accurate blood test to predict cancer incidence, recurrence, guide and monitor treatment intervention
US12390435B2 (en) 2018-11-14 2025-08-19 University of Pittsburgh—of the Commonwealth System of Higher Education Electrophiles and electrophile pro-drugs as RAD51 inhibitors
IT201900003843A1 (it) * 2019-03-15 2020-09-15 Lo Li Pharma Srl Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG)
EP3980006A2 (en) * 2019-06-07 2022-04-13 Diomics Corporation Topical time release delivery using layered biopolymer
WO2021003433A1 (en) * 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
BR112022001165A2 (pt) * 2019-07-23 2022-05-17 Scherer Technologies Llc R P Formulações de cápsula de casca macia e métodos de preparação e uso das mesmas
US11915811B2 (en) * 2019-09-03 2024-02-27 Kaival Labs, Inc. System and method for determining an appropriate dose of a product
KR20220154196A (ko) * 2020-03-18 2022-11-21 알.피.쉐러 테크놀러지즈 엘엘씨 연질겔 캡슐
WO2021231904A1 (en) * 2020-05-14 2021-11-18 Diomics Corporation Detection and indication of covid-19, other viruses and pathogens and vaccine associated efficacy
CN111420046B (zh) * 2020-05-27 2021-01-12 四川省畜牧科学研究院 一种动物疫苗佐剂及其制备方法
WO2022187511A1 (en) * 2021-03-03 2022-09-09 Veramorph Llc Dissociating polymer matrix compositions of fulvestrant and methods of their making and use
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
KR102864596B1 (ko) * 2022-04-25 2025-09-26 유엠에스엔지니어링 주식회사 오메가 3 심리스 연질캡슐 제조방법
WO2025174794A1 (en) * 2024-02-12 2025-08-21 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149851A (en) * 1990-10-25 1992-09-22 The United States Of America As Represented By The Secretary Of Commerce Process for preparing triglycerides containing polyunsaturated fatty acid moieties
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE19738643C2 (de) * 1997-09-04 2001-10-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Scopolaminbase und Verfahren zu seiner Herstellung
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
DE20013336U1 (de) * 2000-08-02 2001-02-15 Bieger, Wilfried P., Priv.-Doz. Dr.med.habil., 80335 München Mund- und Zahnpflegegel
NZ552316A (en) * 2006-12-22 2009-10-30 Fonterra Co Operative Group Dairy product and process
WO2008113177A1 (en) * 2007-03-20 2008-09-25 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US20090068190A1 (en) * 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
WO2014093313A1 (en) * 2012-12-10 2014-06-19 Jingxuan Kang Compositions and methods for integrated metabolic interventions
US8728546B1 (en) * 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
MX370055B (es) * 2013-04-22 2019-11-29 Smartfish As Uso de una composición que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cáncer.
CN103734512A (zh) * 2013-12-20 2014-04-23 晓健科技(大连)有限公司 一种宠物猫补钙营养膏
CA2992282A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders

Similar Documents

Publication Publication Date Title
CN108135177B (zh) 用于治疗癌症的方法
US20180049999A1 (en) Compositions and methods of treatment of breast disorders and estrogen-related disorders
JP2023508325A5 (cg-RX-API-DMAC7.html)
CN111670036A (zh) 包含托法替尼的局部调配物
CA2932106A1 (en) Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
SG175823A1 (en) Use of pufas for treating skin inflammation
ES2877712T3 (es) Terapias combinadas para su uso en el tratamiento del cáncer de mama
JP2021020955A (ja) 経皮製剤
US8680054B2 (en) Suspension type topical formulations comprising cyclic depsipeptide
ES2865254T3 (es) Composiciones para el tratamiento de la vaginitis atrófica, dispareunia perimenopáusica y posmenopaúsica y/o mujeres ooforectomizadas y métodos de tratamiento con las mismas
JP2018520182A5 (cg-RX-API-DMAC7.html)
CN106163280A (zh) 小檗碱制剂及其用途
CN103347498B (zh) 组蛋白脱乙酰酶抑制剂药物配方
TWI510243B (zh) 用於治療膀胱癌的組成物及方法
CN109640958B (zh) 包含选择性雌激素受体调节剂(serm)的阴道递送系统及其用途
TW201919608A (zh) 局部用組合物
JP2021508334A (ja) 男性型禿頭症を含む皮膚障害を処置するための局所製剤
KR20080041695A (ko) O-데스메틸 벤라팍신 (odv) 또는 이의 염을 함유하는국소 제형
TW201919594A (zh) 局部用組合物及治療方法
JP2014024768A (ja) 皮膚外用剤組成物
MX2011001382A (es) Tratamiento de atrofia vaginal en mujeres con riesgo de patologia tumoral.
AU2017285258A1 (en) Compositions comprising timolol and an anti-inflammatory agent
JP2023516754A (ja) 環状デプシペプチドの局所医薬製剤
JP2025528197A (ja) 真菌感染治療のための抗真菌剤の局所送達
JP2016196454A (ja) 涙腺ドラッグデリバリーシステム